In Re: Zetia (Ezetimibe) Antitrust Litigation
Dr. Russell Lamb was retained on behalf of a proposed class of indirect purchasers of branded and generic Zetia tablets in a class action involving allegations of anticompetitive pay-for-delay conduct. In the magistrate’s recommendation to certify the Class, the Court stated “I am satisfied that EPPs have demonstrated a reliable method of calculating damages on a classwide basis…And the damages methodology proposed by Dr. Lamb has been deemed sufficiently reliable to meet that classification in other pharmaceutical antitrust end-payor class actions.”